Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + vindesine + prednisone
- Development stage
- Unknown
- Lead developer
- French Innovative Leukemia Organisation
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CEEP is a combination chemotherapy regimen consisting of cyclophosphamide, epirubicin, vindesine, and prednisone. It was developed by the French Innovative Leukemia Organisation (FILO) as an induction therapy for patients with untreated high-risk (aa-IPI=3) aggressive non-Hodgkin's lymphoma (NHL). The regimen is typically used as a first-line step before consolidation with high-dose therapy (such as the BEAM regimen) and autologous peripheral blood stem cell transplantation. Its components provide a multi-targeted cytotoxic approach: cyclophosphamide acts as a DNA alkylating agent, epirubicin is an anthracycline that inhibits topoisomerase II, vindesine is a vinca alkaloid that disrupts microtubule formation, and prednisone is a corticosteroid with lympholytic properties.
- Other names
- CEEP regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + vindesine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + vindesine + prednisone.